|1.||Burkhart, David J: 2 articles (01/2008 - 12/2005)|
|2.||Koch, Tad H: 2 articles (01/2008 - 12/2005)|
|3.||Post, Glen C: 2 articles (01/2008 - 12/2005)|
|4.||Barthel, Benjamin L: 2 articles (01/2008 - 12/2005)|
|5.||Rudnicki, Daniel L: 1 article (01/2008)|
|6.||Kalet, Brian T: 1 article (01/2008)|
|7.||Hagadorn, John R: 1 article (12/2005)|
|8.||Koch, T H: 1 article (07/2001)|
|9.||Burke, P J: 1 article (07/2001)|
07/01/2001 - "Doxoform (DOXF), a synthetic formaldehyde conjugate of DOX, exhibits enhanced toxicity to numerous sensitive and resistant cancer cell lines. "
01/01/2008 - "Doxsaliform is several fold more active in tumor cell growth inhibition than doxorubicin,but doxazolidine and doxoform are orders of magnitude more active than doxorubicin. "
12/01/2005 - "Both doxoform and doxazolidine inhibit the growth of cancer cells at 1-4 orders of magnitude lower concentration than doxorubicin. "
08/01/1997 - "Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells."
07/01/1999 - "Synthetic formaldehyde conjugates of DOX, DAU, and EPI, denoted Doxoform (DOXF), Daunoform (DAUF), and Epidoxoform (EPIF), exhibit enhanced toxicity to anthracycline-sensitive and -resistant tumor cells. "
|2.||Breast Neoplasms (Breast Cancer)
08/01/1997 - "In spite of hydrolytic instability, Doxoform is 150-fold more toxic to MCF-7 human breast cancer cells and 10000-fold more toxic to MCF-7/ADR resistant cells. "
04/09/1998 - "The recent discovery that the formaldehyde conjugates of doxorubicin and daunorubicin, Doxoform and Daunoform, are cytotoxic to resistant human breast cancer cells prompted the search for hydrolytically more stable anthracycline-formaldehyde conjugates. "
04/09/1998 - "Epidoxoform and epidoxorubicin plus formaldehyde react with the self-complementary DNA octamer (GC)4 to yield five drug-DNA adducts which have structures analogous to the doxorubicin-DNA adducts from reaction of Doxoform with (GC)4. Epidoxoform is 3-fold more toxic to MCF-7 human breast cancer cells and greater than 120-fold more toxic to MCF-7/ADR resistant cells than epidoxorubicin. "
|7.||Complementary DNA (cDNA)